{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:13:57Z","timestamp":1789168437306,"version":"build-2803163510"},"reference-count":19,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Avelumab first\u2010line (1L) maintenance was approved for treatment of advanced urothelial carcinoma (UC) based on results from the JAVELIN Bladder 100 Phase 3 trial. We report real\u2010world data from an early access program (EAP) for avelumab 1L maintenance treatment in Malaysia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from patients with locally advanced or metastatic UC who received \u2265\u00a01 dose of avelumab 1L maintenance treatment between September 2021 and January 2023 were obtained retrospectively. Patient and treatment characteristics, best response to treatment, and safety were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Data were provided from 13 patients treated at 9 hospitals in Malaysia. Seven patients (53.8%) were female, and ECOG performance status prior to 1L chemotherapy was 0\u20131 in 11 patients (84.6%) and 2 in 2 patients (15.4%). Chemotherapy included cisplatin in 6 patients (46.2%) and carboplatin in 7 patients (53.8%), and the best response was complete response in 1 patient (7.7%), partial response in 7 patients (53.8%), and stable disease in 5 patients (38.5%). The median duration of avelumab treatment was 9 months, with treatment ongoing in 4 patients (30.8%) at last follow\u2010up. The objective response rate was 30.8% and an additional 5 patients (38.5%) had stable disease as the best response. Median PFS was 10.4 months. Reasons for discontinuation were disease progression in 8 patients (61.5%) and patient withdrawal in 1 patient (7.7%). Treatment\u2010related adverse events occurred in 3 patients (23.1%) and were grade 2 in 1 patient (7.7%) and grade 1 in 2 (15.4%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Data from this small EAP population support the use of avelumab 1L maintenance treatment in patients with advanced UC in Malaysia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ajco.70042","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T05:55:03Z","timestamp":1763445303000},"page":"744-748","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Avelumab First\u2010Line Maintenance for Advanced Urothelial Carcinoma: Real\u2010World Results From an Early Access Program in Malaysia"],"prefix":"10.1111","volume":"22","author":[{"given":"Fuad Bin","family":"Ismail","sequence":"first","affiliation":[{"name":"Gleneagles Hospital Kuala Lumpur  Kuala Lumpur Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Ibrahim Abdul","family":"Wahid","sequence":"additional","affiliation":[{"name":"Beacon Hospital  Selangor Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthukkumaran","family":"Thiagarajan","sequence":"additional","affiliation":[{"name":"Hospital Kuala Lumpur  Kuala Lumpur Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai Lian","family":"Tan","sequence":"additional","affiliation":[{"name":"Hospital Pulau Pinang  George Town Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nellie Lay Chin","family":"Cheah","sequence":"additional","affiliation":[{"name":"Loh Guan Lye Specialist Hospital  George Town Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai Seng","family":"Lam","sequence":"additional","affiliation":[{"name":"Pantai Hospital Kuala Lumpur  Kuala Lumpur Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris Sze Ying","family":"Chow","sequence":"additional","affiliation":[{"name":"Pantai Hospital Penang  Bayan Lepas Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Fan","family":"Ang","sequence":"additional","affiliation":[{"name":"Penang Adventist Hospital  George Town Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Ng","sequence":"additional","affiliation":[{"name":"Merck Sdn Bhd, Petaling Jaya, Malaysia, an affiliate of Merck KGaA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Loke","sequence":"additional","affiliation":[{"name":"Merck Pte. Ltd., Singapore, an affiliate of Merck KGaA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Seng Hooi","family":"Low","sequence":"additional","affiliation":[{"name":"Affiliation at time of study: Sunway Medical Centre  Selangor Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"\u201cGlobal Cancer Observatory \u201dInternational Agency for Research on Cancer. Accessed on July 20 2025 https:\/\/gco.iarc.fr."},{"key":"e_1_2_12_3_1","unstructured":"\u201cNCCN Clinical Practice Guidelines in Oncology: Bladder Cancer v1.2025 \u201d NCCN."},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.03.001"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.012"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.09.026"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00152-2"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30230-0"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00540-5"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30541-6"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002788"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2023.02.002"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30020143"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2023.06.008"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.09.014"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyac186"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1403120"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmorw.2024.100068"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-015-1108-0"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01792"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.70042","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajco.70042","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.70042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:37:53Z","timestamp":1789166273000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.70042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1111\/ajco.70042"],"URL":"https:\/\/doi.org\/10.1111\/ajco.70042","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"2025-07-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}